Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Misiu, The most forgotten part of the last IC w

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154879
(Total Views: 414)
Posted On: 12/22/2019 2:30:29 PM
Avatar
Posted By: TechGuru
Re: misiu143 #13469
Misiu,

The most forgotten part of the last IC was the one where it was reported that there was "a sustained response for Leronlimab at 8 weeks" for the 1st mTNBC patient.

This is critical for the aspirations of CYDY. The only information we have right now in this one (and anecdotical information about NP's mother. I hope she is still improving), therefore, this bit of information was one of the more important ones (if not the more important) if the IC.

It means that Leronlimab is working and the effect is sustained.

I am a bit apprehensive with the results reported, was expecting the CTC count to go down but, frankly, not to zero and, as well, the suspension/inexistence of stem cells was surprising. I think these results will very unlikely replicate with other patients and we need to have our feet on the ground.

However, in Oncology any improvement is a win, and a reduction of CTC's will, for sure, reduce the metastatic nature of BC and improve the survival time.

How much ?? We don't know. Is this a viable drug ?? You bet, if other patients show a sustainable reduction on CTC this means simply that cancer is being slowed down in one of its most nasty qualities: the ability to propagate.

Now, the fact that there is no intravasion (or this has been diminished according to CTC's count) would mean that probably Leronlimab is stopping the in-situ carcinoma from becoming EMT (invasive carcinoma). This would be very big news as the condition is being "fought" at the root and not latter on when MET are involved.

However, going back to the results, I hope these are similar in the next patients, but, 0 CTC count is very difficult to believe. Maybe I am being paranoid but I always keep on thinking in the "too good to be true".

I will be waiting "like a hawk" for more updates on this, but any positive news can be game-changing. The good thing is that in Oncology, any good news are very good news.

We are living in interesting times with CYDY. I hope the millions of patients of this nasty illness will get relief soon (from Lero or otherwise).

You all enjoy Christmas and the Holiday season.


(3)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us